Hints and tips:
Related Special Reports
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Pfizer was monitoring outbreaks of monkeypox “very closely”, he said....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...I think a lot of people were anticipating a V-shaped recovery . . . People are now waking up the realisation that volatility is going to be normal going forward.”...
...But mild over-the-counter remedies have lost their power to make shareholders in Johnson & Johnson feel good....
...The virus is one of the few major infectious diseases without a vaccine, although recent scientific advances have encouraged four large pharmaceutical companies — Pfizer, GSK, Johnson & Johnson and Moderna...
...A coalition of ethical investors have asked Johnson & Johnson, Merck, Pfizer, Eli Lilly, Gilead, Amgen, Regeneron, Bristol Myers Squibb and AbbVie to publish a report on the process they follow when applying...
...Johnson & Johnson announced in November it had struck a deal to acquire cardiovascular technology group Abiomed for $16.6bn, while Pfizer said in May it had agreed to buy US biotech Biohaven Pharmaceuticals...
...Last month the FDA restricted the use of Johnson & Johnson’s Covid vaccine due to a rare but serious risk of blood clots, which left the Moderna and the BioNTech/Pfizer shots as the only “frontline vaccines...
.... — Andrew Edgecliffe-Johnson ICCR questions Pfizer’s Covid-19 windfall When Pfizer chief executive Albert Bourla goes into a restaurant and gets “a standing ovation because everybody feels that we saved...
...Two doses of the Johnson & Johnson Covid-19 vaccine cut the risk of hospitalisation by up to 85 per cent, according to a South African study conducted when the Omicron coronavirus variant was dominant....
...But it has not made an offer and could decide to target Johnson & Johnson’s consumer healthcare assets, which the US company decided to spin-off in November....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The letter was sent to the boards of Pfizer, Moderna, AstraZeneca and Johnson & Johnson....
...The JCVI said it was proposing a “non-urgent” offer to all children aged 5 to 11 of two doses of a BioNTech/Pfizer paediatric vaccine to be given at least 12 weeks apart....
...Penny Heaton, global head of vaccines for Johnson & Johnson, said her team had begun preparing for the variant as soon as they had secured data....
...Pfizer has avoided many of the controversies that have affected rivals such as Moderna, Johnson & Johnson and AstraZeneca related to rare side effects such as myocarditis and blood clots....
...People vaccinated with the Johnson & Johnson jab are eligible for a booster shot two months after their single vaccine dose....
...The US drugmaker will have delivered 41 per cent of its vaccines to low- and middle-income countries by the end of the year, while Johnson & Johnson will have sent more than half, as production soars in...
...& Johnson’s one-shot jab in February....
...Unlike AstraZeneca and Johnson & Johnson, Pfizer never considered selling its Covid-19 shot without making a profit....
...A year later GSK and Pfizer formed a joint venture from their consumer products divisions, which they plan to spin off next year....
...Johnson & Johnson is to spin off its consumer products division, best known for Band-Aids and baby shampoo, as the world’s largest healthcare company seeks to focus on pharmaceuticals and medical devices...
...This was particularly the case for people who initially received Johnson & Johnson’s one shot jab, a finding that experts believe will prompt many of them to choose mRNA vaccines for their booster doses.J...
International Edition